002612 Lancy Co.,Ltd.
- 18.93
- +0.50+2.71%
Lancy Co.,Ltd. News
Langzi Co., Ltd. (002612): The medical and aesthetic business layout was further expanded under slight pressure in the third quarter
Langzi Co., Ltd. (002612): Performance falls short of expectations; layout of upstream medical and aesthetic equipment production
Langzi Co., Ltd. (002612): The performance is in line with expectations, and the national medical and aesthetic layout is progressing steadily
Langzi Co., Ltd. (002612): It also shows that Beijing Lido and Hunan Yamei's in vitro cultivation models continue to be implemented
Langzi Co., Ltd. (002612): 24H1 performance continues to grow, multi-industry collaborative development
Langzi Co., Ltd. (002612): Profitability has improved significantly, and medical and aesthetic medicine continues to be nationalized
Langzi Co., Ltd. (002612): Zhengzhou Jimei merges with an increasingly perfect medical and aesthetic layout
Langzi Co., Ltd. (002612): Profitability is stable and improving in Q1, medicine and beauty are speeding up the nationwide layout
Langzi Co., Ltd. (002612) 24Q1 financial report review: Zhengzhou Jimei merges to further improve the national medical and aesthetic layout
Langzi Co., Ltd. (002612) Company Information Update Report: Achieved steady overall growth in the first quarter, and the nationalization of medical and aesthetic medicine continues to advance
Langzi Co., Ltd. (002612): Rapid growth in apparel and medical aesthetics, significant improvement in profitability
Langzi Co., Ltd. (002612): Performance is in line with market expectations, clothing is steady, medical and aesthetic growth has achieved recovery
Debon Securities released a research report on April 24 stating that it gave Langzi Shares (002612.SZ) an increase in holdings rating. The main reasons for the rating include: 1) medical and aesthetic business: endogenous growth+epitaxial mergers and acqu
Langzi Co., Ltd. (002612): Profitability improved markedly and continued high-quality growth in medicine and beauty
Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the
Langzi Co., Ltd. (002612): Performance is in line with expectations, and the company continues to grow with high quality
Langzi Co., Ltd. (002612): Medical and aesthetic revenue increased 28% in '23, profitability recovered year on year
Langzi Co., Ltd. (002612): Endogenous extension simultaneously helps medical and aesthetic growth and nurtures stores are expected to gradually reduce losses
Langzi Co., Ltd. (002612): Net profit due to mother increased 953% in 2023, medical and aesthetic business further expanded the chain layout
Langzi Co., Ltd. (002612): The medical and aesthetic business is growing well, profitability is improving, and the nationwide layout is accelerating
No Data
